Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1983 Sep 1;158(3):670–689. doi: 10.1084/jem.158.3.670

Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

PMCID: PMC2187114  PMID: 6411853

Abstract

Human blood mononuclear leukocytes stimulated with toxoplasma antigen, concanavalin A, mezerein plus lentil lectin, or staphylococcal enterotoxin A secreted a factor (macrophage-activating factor, or MAF) that enhanced the capacity of human macrophages to release H2O2 and to kill toxoplasmas. The same lymphoid supernatants contained IFN gamma but not IFN alpha or IFN beta. The MAF activity of six of seven unfractionated supernatants was completely eliminated by a monoclonal antibody that neutralizes IFN gamma, and MAF in the remaining supernatant was almost completely neutralized. Native IFN gamma partially purified by two independent protocols to specific activities of 1 X 10(6) and 10(7) U/mg protein was enriched in MAF activity at least as much as in antiviral activity. The capacity of macrophages to secrete H2O2 after incubation in partially purified native IFN gamma (mean peak stimulation, 8.8-fold) was greater than with unpurified lymphokines (3.8-fold) and sometimes equaled or exceeded the capacity of freshly harvested monocytes. The MAF activity of the partially purified native IFN gamma preparations was abolished by monoclonal anti- IFN gamma. Finally, IFN gamma of greater than 99% estimated purity was isolated (at Genentech, Inc.) from bacteria transformed with the cloned human gene for this lymphokine. Recombinant IFN gamma had potent MAF activity, stimulating the peroxide-releasing capacity of macrophages an average of 19.8-fold at peak response and enhancing their ability to kill toxoplasmas from 2.6 +/- 1.3% for untreated cells to 54 +/- 0.4% for treated cells. Attainment of 50% of the maximal elevation in peroxide-releasing capacity required a geometric mean concentration of 0.1 antiviral U/ml of recombinant IFN gamma, which is estimated to be approximately 6 picomolar for this preparation. Peroxide secretory capacity and toxoplasmacidal activity of macrophages peaked 2-4 d after exposure to IFN gamma. Peroxide-secretory capacity remained elevated during at least 6 d of continuous exposure, but the effect of IFN gamma was reversed within about 3 d of its removal. Activation was usually but not invariably accompanied by characteristic changes in cell morphology. Thus, IFN gamma activates human macrophage oxidative metabolism and antimicrobial activity, and appeared to be the only factor consistently capable of doing so in the diverse LK preparations tested.

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S. E., Bautista S., Remington J. S. Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol. 1976 Aug;117(2):381–387. [PubMed] [Google Scholar]
  2. Basham T. Y., Merigan T. C. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol. 1983 Apr;130(4):1492–1494. [PubMed] [Google Scholar]
  3. Boraschi D., Ghezzi P., Salmona M., Tagliabue A. IFN-beta-induced reduction of superoxide anion generation by macrophages. Immunology. 1982 Apr;45(4):621–628. [PMC free article] [PubMed] [Google Scholar]
  4. Borges J. S., Johnson W. D., Jr Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products. J Exp Med. 1975 Feb 1;141(2):483–496. doi: 10.1084/jem.141.2.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buchmüller Y., Mauel J. Studies on the mechanisms of macrophage activation: possible involvement of oxygen metabolites in killing of Leishmania enrietti by activated mouse macrophages. J Reticuloendothel Soc. 1981 Mar;29(3):181–192. [PubMed] [Google Scholar]
  6. Devos R., Cheroutre H., Taya Y., Degrave W., Van Heuverswyn H., Fiers W. Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res. 1982 Apr 24;10(8):2487–2501. doi: 10.1093/nar/10.8.2487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fleischmann W. R., Jr, Georgiades J. A., Osborne L. C., Dianzani F., Johnson H. M. Induction of an inhibitor of interferon action in a mouse lymphokine preparation. Infect Immun. 1979 Dec;26(3):949–955. doi: 10.1128/iai.26.3.949-955.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fowles R. E., Fajardo I. M., Leibowitch J. L., David J. R. The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med. 1973 Oct 1;138(4):952–964. doi: 10.1084/jem.138.4.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glasgow L. A. Leukocytes and interferon in the host response to viral infections. II. Enhanced interferon response of leukocytes from immune animals. J Bacteriol. 1966 Jun;91(6):2185–2191. doi: 10.1128/jb.91.6.2185-2191.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gober L. L., Friedman-Kien A. E., Havell E. A., Vilcek J. Suppression of the intracellular growth of Shigella flexneri in cell cultures by interferon preparations and polyinosinic-polycytidylic acid. Infect Immun. 1972 Mar;5(3):370–376. doi: 10.1128/iai.5.3.370-376.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gray P. W., Goeddel D. V. Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859–863. doi: 10.1038/298859a0. [DOI] [PubMed] [Google Scholar]
  12. Gray P. W., Leung D. W., Pennica D., Yelverton E., Najarian R., Simonsen C. C., Derynck R., Sherwood P. J., Wallace D. M., Berger S. L. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982 Feb 11;295(5849):503–508. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
  13. Green J. A., Cooperband S. R., Kibrick S. Immune specific induction of interferon production in cultures of human blood lymphocytes. Science. 1969 Jun 20;164(3886):1415–1417. doi: 10.1126/science.164.3886.1415. [DOI] [PubMed] [Google Scholar]
  14. Hamburg S. I., Fleit H. B., Unkeless J. C., Rabinovitch M. Mononuclear phagocytes: responders to and producers of interferon. Ann N Y Acad Sci. 1980;350:72–90. doi: 10.1111/j.1749-6632.1980.tb20609.x. [DOI] [PubMed] [Google Scholar]
  15. Havell E. A., Spitalny G. L., Patel P. J. Enhanced production of murine interferon gamma by T cells generated in response to bacterial infection. J Exp Med. 1982 Jul 1;156(1):112–127. doi: 10.1084/jem.156.1.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hovi T., Saksela O., Vaheri A. Increased secretion of plasminogen activator by human macrophages after exposure to leukocyte interferon. FEBS Lett. 1981 Jul 6;129(2):233–236. doi: 10.1016/0014-5793(81)80172-x. [DOI] [PubMed] [Google Scholar]
  17. Izadkhah Z., Mandel A. D., Sonnenfeld G. Effect of treatment of mice with sera containing gamma interferon on the course of infection with Salmonella typhimurium strain LT-2. J Interferon Res. 1980 Fall;1(1):137–145. doi: 10.1089/jir.1980.1.137. [DOI] [PubMed] [Google Scholar]
  18. Jahiel R. I., Vilcek J., Nussenzweig R. S. Exogenous interferon protects mice against Plasmodium berghei malaria. Nature. 1970 Sep 26;227(5265):1350–1351. doi: 10.1038/2271350a0. [DOI] [PubMed] [Google Scholar]
  19. Jones C. M., Varesio L., Herberman R. B., Pestka S. Interferon activates macrophages to produce plasminogen activator. J Interferon Res. 1982;2(3):377–386. doi: 10.1089/jir.1982.2.377. [DOI] [PubMed] [Google Scholar]
  20. Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983 Apr;130(4):1784–1789. [PubMed] [Google Scholar]
  21. Kazar J., Krautwurst P. A., Gordon F. B. Effect of Interferon and Interferon Inducers on Infections with a Nonviral Intracellular Microorganism, Rickettsia akari. Infect Immun. 1971 Jun;3(6):819–824. doi: 10.1128/iai.3.6.819-824.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Krahenbuhl J. L., Remington J. S. In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun. 1971 Oct;4(4):337–343. doi: 10.1128/iai.4.4.337-343.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  24. Lee S. H., Epstein L. B. Reversible inhibition by interferon of the maturation of human peripheral blood monocytes to macrophages. Cell Immunol. 1980 Mar 1;50(1):177–190. doi: 10.1016/0008-8749(80)90016-7. [DOI] [PubMed] [Google Scholar]
  25. Locksley R. M., Wilson C. B., Klebanoff S. J. Role for endogenous and acquired peroxidase in the toxoplasmacidal activity of murine and human mononuclear phagocytes. J Clin Invest. 1982 May;69(5):1099–1111. doi: 10.1172/JCI110545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mackaness G. B. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med. 1969 May 1;129(5):973–992. doi: 10.1084/jem.129.5.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mizrahi A., O'Malley J. A., Carter W. A., Takatsuki A., Tamura G., Sulkowski E. Glycosylation of interferons. Effects of tunicamycin on human immune interferon. J Biol Chem. 1978 Nov 10;253(21):7612–7615. [PubMed] [Google Scholar]
  28. Mizunoe K., Hiraki M., Nagano Y., Maehara N. Suppression of intracellular multiplication of Mycobacterium tuberculosis by virus-inhibiting factor or interferon. Jpn J Microbiol. 1975 Jun;19(3):235–236. doi: 10.1111/j.1348-0421.1975.tb00875.x. [DOI] [PubMed] [Google Scholar]
  29. Murray H. W., Cartelli D. M. Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J Clin Invest. 1983 Jul;72(1):32–44. doi: 10.1172/JCI110972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Murray H. W., Cohn Z. A. Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med. 1980 Dec 1;152(6):1596–1609. doi: 10.1084/jem.152.6.1596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Murray H. W., Juangbhanich C. W., Nathan C. F., Cohn Z. A. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med. 1979 Oct 1;150(4):950–964. doi: 10.1084/jem.150.4.950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nakagawara A., DeSantis N. M., Nogueira N., Nathan C. F. Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest. 1982 Nov;70(5):1042–1048. doi: 10.1172/JCI110691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nakagawara A., Nathan C. F., Cohn Z. A. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest. 1981 Nov;68(5):1243–1252. doi: 10.1172/JCI110370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Nathan C. F., Karnovsky M. L., David J. R. Alterations of macrophage functions by mediators from lymphocytes. J Exp Med. 1971 Jun 1;133(6):1356–1376. doi: 10.1084/jem.133.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nathan C. F., Remold H. G., David J. R. Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med. 1973 Feb 1;137(2):275–290. doi: 10.1084/jem.137.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Nathan C., Nogueira N., Juangbhanich C., Ellis J., Cohn Z. Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med. 1979 May 1;149(5):1056–1068. doi: 10.1084/jem.149.5.1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Nogueira N., Cohn Z. A. Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. J Exp Med. 1978 Jul 1;148(1):288–300. doi: 10.1084/jem.148.1.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pabst M. J., Hedegaard H. B., Johnston R. B., Jr Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response. J Immunol. 1982 Jan;128(1):123–128. [PubMed] [Google Scholar]
  39. Pace J. L., Russell S. W., Torres B. A., Johnson H. M., Gray P. W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 1983 May;130(5):2011–2013. [PubMed] [Google Scholar]
  40. Pillemer E., Weissman I. L. A monoclonal antibody that detects a V kappa-TEPC15 idiotypic determinant cross-reactive with a Thy-1 determinant. J Exp Med. 1981 May 1;153(5):1068–1079. doi: 10.1084/jem.153.5.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Remington J. S., Merigan T. C. Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science. 1968 Aug 23;161(3843):804–806. doi: 10.1126/science.161.3843.804. [DOI] [PubMed] [Google Scholar]
  42. Rubin B. Y., Bartal A. H., Anderson S. L., Millet S. K., Hirshaut Y., Feit C. The anticellular and protein-inducing activities of human gamma interferon preparations are mediated by the interferon. J Immunol. 1983 Mar;130(3):1019–1020. [PubMed] [Google Scholar]
  43. Rubin B. Y., Gupta S. L. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci U S A. 1980 Oct;77(10):5928–5932. doi: 10.1073/pnas.77.10.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sakurai H., Takei Y., Omata Y., Suzuki N. Production and properties of Toxoplasma growth inhibitory factor (Toxo-GIF) and interferon (IFN) in the lymphokines and the circulation of Toxoplasma immune mice. Zentralbl Bakteriol Mikrobiol Hyg A. 1981 Dec;251(1):134–143. [PubMed] [Google Scholar]
  45. Salvin S. B., Youngner J. S., Lederer W. H. Migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. Infect Immun. 1973 Jan;7(1):68–75. doi: 10.1128/iai.7.1.68-75.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Shirahata T., Shimizu K. Production and properties of immune interferon from spleen cell cultures of Toxoplasma-infected mice. Microbiol Immunol. 1980;24(11):1109–1120. doi: 10.1111/j.1348-0421.1980.tb02915.x. [DOI] [PubMed] [Google Scholar]
  47. Steeg P. S., Moore R. N., Johnson H. M., Oppenheim J. J. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med. 1982 Dec 1;156(6):1780–1793. doi: 10.1084/jem.156.6.1780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Szuro-Sudol A., Nathan C. F. Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med. 1982 Oct 1;156(4):945–961. doi: 10.1084/jem.156.4.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wheelock E. F. Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin. Science. 1965 Jul 16;149(3681):310–311. doi: 10.1126/science.149.3681.310. [DOI] [PubMed] [Google Scholar]
  50. Yip Y. K., Pang R. H., Oppenheim J. D., Nachbar M. S., Henriksen D., Zerebeckyj-Eckhardt I., Vilcek J. Stimulation of human gamma interferon production by diterpene esters. Infect Immun. 1981 Oct;34(1):131–139. doi: 10.1128/iai.34.1.131-139.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES